Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952 | 1.00 | MEN1 (0.47) | MEN1KMT2ACES2BCHEACHE | |
| Water SCHEMBL28189365 | 1.00 | MEN1 (0.47) | MEN1KMT2ACES2BCHEACHE | |
| Hydrochloric Acid SCHEMBL8130707 | 0.97 | CES2 (0.44) | MEN1KMT2ACES2BCHEACHE | |
| SCHEMBL28071586 | 0.97 | CES2 (0.44) | MEN1KMT2ACES2BCHEACHE | |
| SCHEMBL9196667 | 0.94 | CES2 (0.42) | MEN1KMT2ACES2BCHEACHE | |
| Methylene Chloride SCHEMBL28153470 | 0.92 | CES2 (0.40) | MEN1KMT2ACES2BCHEACHE | |
| Acetonitrile SCHEMBL29137992 | 0.92 | CES2 (0.40) | MEN1KMT2ACES2BCHEACHE | |
| Benzoquinone SCHEMBL5262501 | 0.87 | BCHE (0.38) | MEN1KMT2ACES2BCHEACHE | |
| SCHEMBL10296285 | 0.87 | CES2 (0.36) | MEN1KMT2ACES2BCHEACHE | |
| SCHEMBL383049 | 0.86 | CES2 (0.45) | MEN1KMT2ACES2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307518-A | Polycyclic PARP selective inhibitors | 轩竹生物科技股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-117924310-A | Macrocyclic compounds and uses thereof | 哈佛大学的校长及成员们 | 2024-04-26 | — | — | CN | disclosed |
| CN-112752760-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-19 | — | — | CN | disclosed |
| CN-111566113-B | Macrocyclic compounds and uses thereof | 哈佛大学的校长及成员们 | 2024-01-09 | — | — | CN | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-114957354-B | Heparin pentasaccharide structure compound | 南开大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-115109111-B | Production process of progestogen | 天津市中升挑战生物科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116854752-A | Heparin trisaccharide structure compound and pharmaceutical application thereof | 南开大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-116761605-A | Salts and crystalline forms of HA inhibitor compounds | 四川海思科制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116672350-A | Application of heparin pentasaccharide compound in preparation of medicament for treating viral hemorrhagic fever | 南开大学 | 2023-09-01 | — | — | CN | disclosed |
| WO-2016144848-A1 | PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20150061457-A1 | ACTUATOR ELEMENT USING CARBON ELECTRODE | NATIONAL INSTITUTE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2833542-A1 | ACTUATOR ELEMENT USING CARBON ELECTRODE | National Institute Of Advanced Industrial Science (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2049563-B1 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARM CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2409984-A1 | Dimeric IAP Antagonists | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7985735-B2 | mimetics of the activity of the N-terminal portion of Smac/tertiary binding structure to IAPs, can be combined with chemotherapeutic agents like topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds; increased cell permeability, water solubility; antitumor agents | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2049563-A2 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008014263-A2 | DIMERIC IAP ANTAGONISTS | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-5262085-A | FOR USE IN LIQUID CRYSTAL AND ELECTROOPTICAL DISPLAY ELEMENTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020986-A1 | DIMERIC IAP INHIBITORS | BIRC2, BIRC7, BIRC8 | MEN1 1628/4885KMT2A 3244/4885CES2 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.